- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Strong Past Earnings Growth, P/E Ratio Below 20
U.S. Pharmaceuticals & Biotech Strong Past Earnings Growth, P/E Ratio Below 20
Results
3
1 new
A list of companies that grew earnings by 20% and are trading on less than 20 times earnings. All with a debt to equity ratio below 1.
3 companies
Exelixis
Market Cap: US$11.2b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$42.42
7D
2.4%
1Y
22.9%
BioStem Technologies
Market Cap: US$66.6m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
New
BSEM
US$3.35
7D
-27.2%
1Y
-75.4%
Earth Science Tech
Market Cap: US$41.6m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.14
7D
-12.5%
1Y
16.8%